Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 5701 to 5712 of 5712 entries
Sorted by: Best Match Show Resources per page
The Extrapolation Performance of Survival Models for Data With a Cure Fraction: A Simulation Study.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Kearns B, Stevenson MD, Triantafyllopoulos K, Manca A.
PMID: 34711364
Value Health. 2021 Nov;24(11):1634-1642. doi: 10.1016/j.jval.2021.05.009. Epub 2021 Jul 28.

OBJECTIVES: Curative treatments can result in complex hazard functions. The use of standard survival models may result in poor extrapolations. Several models for data which may have a cure fraction are available, but comparisons of their extrapolation performance are...

Cite
Kearns B, Stevenson MD, Triantafyllopoulos K, et al. The Extrapolation Performance of Survival Models for Data With a Cure Fraction: A Simulation Study. Value Health. 2021;24(11):1634-1642doi: 10.1016/j.jval.2021.05.009.
Kearns, B., Stevenson, M. D., Triantafyllopoulos, K., & Manca, A. (2021). The Extrapolation Performance of Survival Models for Data With a Cure Fraction: A Simulation Study. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 24(11), 1634-1642. https://doi.org/10.1016/j.jval.2021.05.009
Kearns, Benjamin, et al. "The Extrapolation Performance of Survival Models for Data With a Cure Fraction: A Simulation Study." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 24,11 (2021): 1634-1642. doi: https://doi.org/10.1016/j.jval.2021.05.009
Kearns B, Stevenson MD, Triantafyllopoulos K, Manca A. The Extrapolation Performance of Survival Models for Data With a Cure Fraction: A Simulation Study. Value Health. 2021 Nov;24(11):1634-1642. doi: 10.1016/j.jval.2021.05.009. Epub 2021 Jul 28. PMID: 34711364.
Copy Download .nbib Format: NLM
Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Garrison LP, Pezalla E, Towse A, Yang H, Faust E, Wu EQ, Li N, Sawyer EK, Recht M.
PMID: 34711363
Value Health. 2021 Nov;24(11):1628-1633. doi: 10.1016/j.jval.2021.05.008. Epub 2021 Oct 03.

Gene therapy for hemophilia is designed to produce health gains for patients over many years. Rewarding that value creation on the basis of a one-time treatment implies a large upfront cost. This cost can only be justified by long-term...

Cite
Garrison LP, Pezalla E, Towse A, et al. Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations. Value Health. 2021;24(11):1628-1633doi: 10.1016/j.jval.2021.05.008.
Garrison, L. P., Pezalla, E., Towse, A., Yang, H., Faust, E., Wu, E. Q., Li, N., Sawyer, E. K., & Recht, M. (2021). Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 24(11), 1628-1633. https://doi.org/10.1016/j.jval.2021.05.008
Garrison, Louis P, et al. "Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 24,11 (2021): 1628-1633. doi: https://doi.org/10.1016/j.jval.2021.05.008
Garrison LP, Pezalla E, Towse A, Yang H, Faust E, Wu EQ, Li N, Sawyer EK, Recht M. Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations. Value Health. 2021 Nov;24(11):1628-1633. doi: 10.1016/j.jval.2021.05.008. Epub 2021 Oct 03. PMID: 34711363.
Copy Download .nbib Format: NLM
Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative.

Circulation

Franklin JM, Patorno E, Desai RJ, Glynn RJ, Martin D, Quinto K, Pawar A, Bessette LG, Lee H, Garry EM, Gautam N, Schneeweiss S.
PMID: 33327727
Circulation. 2021 Mar 09;143(10):1002-1013. doi: 10.1161/CIRCULATIONAHA.120.051718. Epub 2020 Dec 17.

BACKGROUND: Regulators are evaluating the use of noninterventional real-world evidence (RWE) studies to assess the effectiveness of medical products. The RCT DUPLICATE initiative (Randomized, Controlled Trials Duplicated Using Prospective Longitudinal Insurance Claims: Applying Techniques of Epidemiology) uses a structured...

Cite
Franklin JM, Patorno E, Desai RJ, et al. Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative. Circulation. 2020;143(10):1002-1013doi: 10.1161/CIRCULATIONAHA.120.051718.
Franklin, J. M., Patorno, E., Desai, R. J., Glynn, R. J., Martin, D., Quinto, K., Pawar, A., Bessette, L. G., Lee, H., Garry, E. M., Gautam, N., & Schneeweiss, S. (2021). Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative. Circulation, 143(10), 1002-1013. https://doi.org/10.1161/CIRCULATIONAHA.120.051718
Franklin, Jessica M, et al. "Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative." Circulation vol. 143,10 (2021): 1002-1013. doi: https://doi.org/10.1161/CIRCULATIONAHA.120.051718
Franklin JM, Patorno E, Desai RJ, Glynn RJ, Martin D, Quinto K, Pawar A, Bessette LG, Lee H, Garry EM, Gautam N, Schneeweiss S. Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative. Circulation. 2021 Mar 09;143(10):1002-1013. doi: 10.1161/CIRCULATIONAHA.120.051718. Epub 2020 Dec 17. PMID: 33327727; PMCID: PMC7940583.
Copy Download .nbib Format: NLM
Pharmacist's Perspectives on Administering a COVID-19 Vaccine in Community Pharmacies in Four Balkan Countries.

Frontiers in public health

Turcu-Stiolica A, Kamusheva M, Bogdan M, Tadic I, Harasani K, Subtirelu MS, Meca AD, Šesto S, Odalović M, Arsić J, Stojkov S, Terzieva E, Petrova G.
PMID: 34900910
Front Public Health. 2021 Nov 25;9:766146. doi: 10.3389/fpubh.2021.766146. eCollection 2021.

Community pharmacists expanded their roles and engaged in vaccination services in many countries around the world, but not in Balkan countries. This research aimed to assess the perceptions of pharmacists on involvement in the coronavirus disease (COVID-19) vaccine administration...

Cite
Turcu-Stiolica A, Kamusheva M, Bogdan M, et al. Pharmacist's Perspectives on Administering a COVID-19 Vaccine in Community Pharmacies in Four Balkan Countries. Front Public Health. 2021;9:766146doi: 10.3389/fpubh.2021.766146.
Turcu-Stiolica, A., Kamusheva, M., Bogdan, M., Tadic, I., Harasani, K., Subtirelu, M. S., Meca, A. D., Šesto, S., Odalović, M., Arsić, J., Stojkov, S., Terzieva, E., & Petrova, G. (2021). Pharmacist's Perspectives on Administering a COVID-19 Vaccine in Community Pharmacies in Four Balkan Countries. Frontiers in public health, 9766146. https://doi.org/10.3389/fpubh.2021.766146
Turcu-Stiolica, Adina, et al. "Pharmacist's Perspectives on Administering a COVID-19 Vaccine in Community Pharmacies in Four Balkan Countries." Frontiers in public health vol. 9 (2021): 766146. doi: https://doi.org/10.3389/fpubh.2021.766146
Turcu-Stiolica A, Kamusheva M, Bogdan M, Tadic I, Harasani K, Subtirelu MS, Meca AD, Šesto S, Odalović M, Arsić J, Stojkov S, Terzieva E, Petrova G. Pharmacist's Perspectives on Administering a COVID-19 Vaccine in Community Pharmacies in Four Balkan Countries. Front Public Health. 2021 Nov 25;9:766146. doi: 10.3389/fpubh.2021.766146. eCollection 2021. PMID: 34900910; PMCID: PMC8655838.
Copy Download .nbib Format: NLM
Do indicators for the proportion of pharmaceutical spending alleviate the burden of medical expenditure? Evidence from provincial panel-data in China, 2010-2019.

Expert review of pharmacoeconomics & outcomes research

Yang T, Deng W, Zhao W, Liu J, Deng J.
PMID: 33866909
Expert Rev Pharmacoecon Outcomes Res. 2021 Apr 21;1-9. doi: 10.1080/14737167.2021.1917999. Epub 2021 Apr 21.

BACKGROUND: The current study aims to empirically evaluate the direct relationship between the proportion of pharmaceutical spending and total medical expenditure in China in a recent decade period.METHODS: A two-way fixed-effect model was established to estimate the relationship between...

Cite
Yang T, Deng W, Zhao W, et al. Do indicators for the proportion of pharmaceutical spending alleviate the burden of medical expenditure? Evidence from provincial panel-data in China, 2010-2019. Expert Rev Pharmacoecon Outcomes Res. 2021;1-9doi: 10.1080/14737167.2021.1917999.
Yang, T., Deng, W., Zhao, W., Liu, J., & Deng, J. (2021). Do indicators for the proportion of pharmaceutical spending alleviate the burden of medical expenditure? Evidence from provincial panel-data in China, 2010-2019. Expert review of pharmacoeconomics & outcomes research, 1-9. https://doi.org/10.1080/14737167.2021.1917999
Yang, Tianan, et al. "Do indicators for the proportion of pharmaceutical spending alleviate the burden of medical expenditure? Evidence from provincial panel-data in China, 2010-2019." Expert review of pharmacoeconomics & outcomes research vol. (2021): 1-9. doi: https://doi.org/10.1080/14737167.2021.1917999
Yang T, Deng W, Zhao W, Liu J, Deng J. Do indicators for the proportion of pharmaceutical spending alleviate the burden of medical expenditure? Evidence from provincial panel-data in China, 2010-2019. Expert Rev Pharmacoecon Outcomes Res. 2021 Apr 21;1-9. doi: 10.1080/14737167.2021.1917999. Epub 2021 Apr 21. PMID: 33866909.
Copy Download .nbib Format: NLM
Cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer in China.

Expert review of pharmacoeconomics & outcomes research

Liu G, Kang S.
PMID: 33627014
Expert Rev Pharmacoecon Outcomes Res. 2022 Jan;22(1):85-91. doi: 10.1080/14737167.2021.1888717. Epub 2021 Feb 25.

OBJECTIVES: Durvalumab plus chemotherapy could significantly improve overall survival compared with chemotherapy alone in the first-line treatment of extensive-stage small-cell lung cancer (SCLC). However, its long-term economic outcomes remain unclear yet. This study aimed to evaluate the cost-effectiveness of...

Cite
Liu G, Kang S. Cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer in China. Expert Rev Pharmacoecon Outcomes Res. 2021;22(1):85-91doi: 10.1080/14737167.2021.1888717.
Liu, G., & Kang, S. (2022). Cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer in China. Expert review of pharmacoeconomics & outcomes research, 22(1), 85-91. https://doi.org/10.1080/14737167.2021.1888717
Liu, Guoqiang, and Kang, Shuo. "Cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer in China." Expert review of pharmacoeconomics & outcomes research vol. 22,1 (2022): 85-91. doi: https://doi.org/10.1080/14737167.2021.1888717
Liu G, Kang S. Cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer in China. Expert Rev Pharmacoecon Outcomes Res. 2022 Jan;22(1):85-91. doi: 10.1080/14737167.2021.1888717. Epub 2021 Feb 25. PMID: 33627014.
Copy Download .nbib Format: NLM
Entheseal involvement in a group of psoriatic arthritis patients: An ultrasonographic study.

Experimental and therapeutic medicine

Chisălău BA, Bărbulescu AL, Pârvănescu CD, Firulescu SC, Dinescu ȘC, Dumitrașcu RM, Turcu-Stiolica A, Ionescu RA, Popoviciu HV, Covei SB, Boldeanu MV, Vilcea AM, Ciurea PL, Vreju FA.
PMID: 34373730
Exp Ther Med. 2021 Sep;22(3):1044. doi: 10.3892/etm.2021.10476. Epub 2021 Jul 21.

Psoriatic arthritis (PsA) is an inflammatory potentially destructive disease that requires early diagnosis and therapeutic approach. Its main pathogenic event and the condition's hallmark is considered to be enthesitis. Clinical examination of the enthesis can be a challenge in...

Cite
Chisălău BA, Bărbulescu AL, Pârvănescu CD, et al. Entheseal involvement in a group of psoriatic arthritis patients: An ultrasonographic study. Exp Ther Med. 2021;22(3):1044doi: 10.3892/etm.2021.10476.
Chisălău, B. A., Bărbulescu, A. L., Pârvănescu, C. D., Firulescu, S. C., Dinescu, �. �. C., Dumitrașcu, R. M., Turcu-Stiolica, A., Ionescu, R. A., Popoviciu, H. V., Covei, S. B., Boldeanu, M. V., Vilcea, A. M., Ciurea, P. L., & Vreju, F. A. (2021). Entheseal involvement in a group of psoriatic arthritis patients: An ultrasonographic study. Experimental and therapeutic medicine, 22(3), 1044. https://doi.org/10.3892/etm.2021.10476
Chisălău, Beatrice Andreea, et al. "Entheseal involvement in a group of psoriatic arthritis patients: An ultrasonographic study." Experimental and therapeutic medicine vol. 22,3 (2021): 1044. doi: https://doi.org/10.3892/etm.2021.10476
Chisălău BA, Bărbulescu AL, Pârvănescu CD, Firulescu SC, Dinescu ȘC, Dumitrașcu RM, Turcu-Stiolica A, Ionescu RA, Popoviciu HV, Covei SB, Boldeanu MV, Vilcea AM, Ciurea PL, Vreju FA. Entheseal involvement in a group of psoriatic arthritis patients: An ultrasonographic study. Exp Ther Med. 2021 Sep;22(3):1044. doi: 10.3892/etm.2021.10476. Epub 2021 Jul 21. PMID: 34373730; PMCID: PMC8343913.
Copy Download .nbib Format: NLM
State of health economic evaluation research in Saudi Arabia: a review.

ClinicoEconomics and outcomes research : CEOR

Al-Aqeel SA.
PMID: 22826634
Clinicoecon Outcomes Res. 2012;4:177-84. doi: 10.2147/CEOR.S31087. Epub 2012 Jul 05.

BACKGROUND: If evaluation of economic evidence is to be used increasingly in Saudi Arabia, a review of the published literature would be useful to inform policy decision-makers of the current state of research and plan future research agendas. The...

Cite
Al-Aqeel SA. State of health economic evaluation research in Saudi Arabia: a review. Clinicoecon Outcomes Res. 2012;4:177-84doi: 10.2147/CEOR.S31087.
Al-Aqeel, S. A. (2012). State of health economic evaluation research in Saudi Arabia: a review. ClinicoEconomics and outcomes research : CEOR, 4177-84. https://doi.org/10.2147/CEOR.S31087
Al-Aqeel, Sinaa A. "State of health economic evaluation research in Saudi Arabia: a review." ClinicoEconomics and outcomes research : CEOR vol. 4 (2012): 177-84. doi: https://doi.org/10.2147/CEOR.S31087
Al-Aqeel SA. State of health economic evaluation research in Saudi Arabia: a review. Clinicoecon Outcomes Res. 2012;4:177-84. doi: 10.2147/CEOR.S31087. Epub 2012 Jul 05. PMID: 22826634; PMCID: PMC3401052.
Copy Download .nbib Format: NLM
Budget impact analysis of pneumococcal conjugate vaccines in Colombia. Response to letter to the editor.

Expert review of pharmacoeconomics & outcomes research

Gomez JA, Caceres D, Rodriguez E.
PMID: 34612137
Expert Rev Pharmacoecon Outcomes Res. 2022 Jan;22(1):5-6. doi: 10.1080/14737167.2022.1986007. Epub 2021 Oct 06.

No abstract available.

Cite
Gomez JA, Caceres D, Rodriguez E. Budget impact analysis of pneumococcal conjugate vaccines in Colombia. Response to letter to the editor. Expert Rev Pharmacoecon Outcomes Res. 2021;22(1):5-6doi: 10.1080/14737167.2022.1986007.
Gomez, J. A., Caceres, D., & Rodriguez, E. (2022). Budget impact analysis of pneumococcal conjugate vaccines in Colombia. Response to letter to the editor. Expert review of pharmacoeconomics & outcomes research, 22(1), 5-6. https://doi.org/10.1080/14737167.2022.1986007
Gomez, Jorge A, et al. "Budget impact analysis of pneumococcal conjugate vaccines in Colombia. Response to letter to the editor." Expert review of pharmacoeconomics & outcomes research vol. 22,1 (2022): 5-6. doi: https://doi.org/10.1080/14737167.2022.1986007
Gomez JA, Caceres D, Rodriguez E. Budget impact analysis of pneumococcal conjugate vaccines in Colombia. Response to letter to the editor. Expert Rev Pharmacoecon Outcomes Res. 2022 Jan;22(1):5-6. doi: 10.1080/14737167.2022.1986007. Epub 2021 Oct 06. PMID: 34612137.
Copy Download .nbib Format: NLM
Costs of providing COVID 19-protective measures during routine immunisation in lower-income countries?.

PharmacoEconomics & outcomes news

[No authors listed]
PMID: 34429576
PharmacoEcon Outcomes News. 2021;885(1):4. doi: 10.1007/s40274-021-07946-y. Epub 2021 Aug 21.

No abstract available.

Cite
Costs of providing COVID 19-protective measures during routine immunisation in lower-income countries?. PharmacoEcon Outcomes News. 2021;885(1):4doi: 10.1007/s40274-021-07946-y.
(2021). Costs of providing COVID 19-protective measures during routine immunisation in lower-income countries?. PharmacoEconomics & outcomes news, 885(1), 4. https://doi.org/10.1007/s40274-021-07946-y
"Costs of providing COVID 19-protective measures during routine immunisation in lower-income countries?." PharmacoEconomics & outcomes news vol. 885,1 (2021): 4. doi: https://doi.org/10.1007/s40274-021-07946-y
Costs of providing COVID 19-protective measures during routine immunisation in lower-income countries?. PharmacoEcon Outcomes News. 2021;885(1):4. doi: 10.1007/s40274-021-07946-y. Epub 2021 Aug 21. PMID: 34429576; PMCID: PMC8377326.
Copy Download .nbib Format: NLM
Expediting Patient Access to New Health Technologies: Role of Disease-Specific Reference Models.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Haji Ali Afzali H, Karnon J.
PMID: 34119072
Value Health. 2021 Jun;24(6):755-758. doi: 10.1016/j.jval.2020.12.013. Epub 2021 Mar 13.

No abstract available.

Cite
Haji Ali Afzali H, Karnon J. Expediting Patient Access to New Health Technologies: Role of Disease-Specific Reference Models. Value Health. 2021;24(6):755-758doi: 10.1016/j.jval.2020.12.013.
Haji Ali Afzali, H., & Karnon, J. (2021). Expediting Patient Access to New Health Technologies: Role of Disease-Specific Reference Models. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 24(6), 755-758. https://doi.org/10.1016/j.jval.2020.12.013
Haji Ali Afzali, Hossein, and Karnon, Jonathan. "Expediting Patient Access to New Health Technologies: Role of Disease-Specific Reference Models." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 24,6 (2021): 755-758. doi: https://doi.org/10.1016/j.jval.2020.12.013
Haji Ali Afzali H, Karnon J. Expediting Patient Access to New Health Technologies: Role of Disease-Specific Reference Models. Value Health. 2021 Jun;24(6):755-758. doi: 10.1016/j.jval.2020.12.013. Epub 2021 Mar 13. PMID: 34119072.
Copy Download .nbib Format: NLM
Does Cost-Effectiveness Analysis Overvalue Potential Cures? Exploring Alternative Methods for Applying a "Shared Savings" Approach to Cost Offsets.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Chapman RH, Kumar VM, Whittington MD, Pearson SD.
PMID: 34119082
Value Health. 2021 Jun;24(6):839-845. doi: 10.1016/j.jval.2021.02.008. Epub 2021 May 10.

OBJECTIVES: To evaluate alternative methods to calculate and/or attribute economic surplus in the cost-effectiveness analysis of single or short-term therapies.METHODS: We performed a systematic literature review of articles describing alternative methods for cost-effectiveness analysis of potentially curative therapies whose...

Cite
Chapman RH, Kumar VM, Whittington MD, et al. Does Cost-Effectiveness Analysis Overvalue Potential Cures? Exploring Alternative Methods for Applying a "Shared Savings" Approach to Cost Offsets. Value Health. 2021;24(6):839-845doi: 10.1016/j.jval.2021.02.008.
Chapman, R. H., Kumar, V. M., Whittington, M. D., & Pearson, S. D. (2021). Does Cost-Effectiveness Analysis Overvalue Potential Cures? Exploring Alternative Methods for Applying a "Shared Savings" Approach to Cost Offsets. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 24(6), 839-845. https://doi.org/10.1016/j.jval.2021.02.008
Chapman, Richard H, et al. "Does Cost-Effectiveness Analysis Overvalue Potential Cures? Exploring Alternative Methods for Applying a "Shared Savings" Approach to Cost Offsets." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 24,6 (2021): 839-845. doi: https://doi.org/10.1016/j.jval.2021.02.008
Chapman RH, Kumar VM, Whittington MD, Pearson SD. Does Cost-Effectiveness Analysis Overvalue Potential Cures? Exploring Alternative Methods for Applying a "Shared Savings" Approach to Cost Offsets. Value Health. 2021 Jun;24(6):839-845. doi: 10.1016/j.jval.2021.02.008. Epub 2021 May 10. PMID: 34119082.
Copy Download .nbib Format: NLM
Showing 5701 to 5712 of 5712 entries